NEWRON PHARMACEUT. EO-,20/ IT0004147952 /
| 15/11/2024 23:00:52 | Chg. -0.280 | Volume | Bid23:00:52 | Ask23:00:52 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 7.760EUR | -3.48% | - Turnover: - |
7.760Bid Size: - | 7.900Ask Size: - | 138.75 mill.EUR | - | - |
Assets
| 2014 IFRS in mill. EUR |
2015 IFRS in mill. EUR |
2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | .1000 | .1000 | .1000 | .1000 | .1000 | ||||||
| Intangible Assets | 7 | .3000 | .3000 | 0.0000 | 0.0000 | ||||||
| Long-Term Investments | .6000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Fixed Assets | 7.7000 | .4000 | .5000 | .2000 | .2000 | ||||||
| Inventories | .1000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 18.8000 | 36 | 42.9000 | 56.3000 | 27.6000 | ||||||
| Current Assets | 29.4000 | 44 | 56.1000 | 72.8000 | 59.5000 | ||||||
| Total Assets | 37.1000 | 44.4000 | 56.6000 | 73 | 59.7000 | ||||||
Liabilities
| 2014 IFRS in mill. EUR |
2015 IFRS in mill. EUR |
2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 3.8000 | 6.2000 | 6.3000 | 4.7000 | 4.3000 | ||||||
| Long-term debt | .7000 | .4000 | - | - | - | ||||||
| Liabilities to Banks | 1.1000 | .8000 | .4000 | 0.0000 | 0.0000 | ||||||
| Provisions | 2.3000 | .1000 | .1000 | - | - | ||||||
| Liabilities | 7.8000 | 7.3000 | 6.8000 | 5.3000 | 4.9000 | ||||||
| Share Capital | 2.6000 | 2.8000 | 3.2000 | 3.6000 | 3.6000 | ||||||
| Total Equity | 29.3000 | 37.1000 | 49.7000 | 67.7000 | 54.8000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 37.1000 | 44.4000 | 56.6000 | 73 | 59.7000 | ||||||
Income Statement
| 2014 IFRS in mill. EUR |
2015 IFRS in mill. EUR |
2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1.6000 | 2.4000 | 6.7000 | 13.4000 | 4 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -11.2000 | -24.4000 | -15.3000 | -4.3000 | -15 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | -10.7000 | -25 | -15.2000 | -5.3000 | -15 | ||||||
| Income Taxes | .6000 | 2.2000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | -10.1000 | -22.8000 | -15.2000 | -5.3000 | -15 | ||||||
Per Share
Cash Flow
| 2014 IFRS in mill. EUR |
2015 IFRS in mill. EUR |
2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -10 | -12.9000 | -19.6000 | -8.4000 | -16.1000 | ||||||
| Cash Flow from Investing Activities | -6.9000 | 2.1000 | 1.4000 | -.2000 | 3 | ||||||
| Cash Flow from Financing | 17.2000 | 28 | 25.1000 | 22 | .1000 | ||||||
| Decrease / Increase in Cash | .3000 | 17.3000 | 6.9000 | 13.3000 | -13 | ||||||
| Employees | 23 | 23 | 23 | 23 | 24 | ||||||
